Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Amortization of Deferred Charges (2016 - 2025)

Historic Amortization of Deferred Charges for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $495000.0.

  • Ocular Therapeutix's Amortization of Deferred Charges fell 1406.25% to $495000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $3.4 million, marking a year-over-year decrease of 902.52%. This contributed to the annual value of $3.4 million for FY2025, which is 902.52% down from last year.
  • Ocular Therapeutix's Amortization of Deferred Charges amounted to $495000.0 in Q4 2025, which was down 1406.25% from $758000.0 recorded in Q3 2025.
  • Ocular Therapeutix's 5-year Amortization of Deferred Charges high stood at $2.1 million for Q3 2023, and its period low was $495000.0 during Q4 2025.
  • For the 5-year period, Ocular Therapeutix's Amortization of Deferred Charges averaged around $1.1 million, with its median value being $1.2 million (2021).
  • In the last 5 years, Ocular Therapeutix's Amortization of Deferred Charges surged by 6914.29% in 2023 and then tumbled by 7002.9% in 2024.
  • Ocular Therapeutix's Amortization of Deferred Charges (Quarter) stood at $1.2 million in 2021, then grew by 4.12% to $1.2 million in 2022, then rose by 25.55% to $1.6 million in 2023, then tumbled by 62.91% to $576000.0 in 2024, then decreased by 14.06% to $495000.0 in 2025.
  • Its Amortization of Deferred Charges was $495000.0 in Q4 2025, compared to $758000.0 in Q3 2025 and $708000.0 in Q2 2025.